EVOK stock forecast
Our latest prediction for Evoke Pharma, Inc.'s stock price was made on the Aug. 20, 2018 when the stock price was at 2.38$.
In the short term (2weeks), EVOK's stock price should outperform the market by 5.38%. During that period the price should oscillate between -7.98% and +14.50%.
In the medium term (3months), EVOK's stock price should outperform the market by 9.28%. During that period the price should oscillate between -18.15% and +33.76%.Get email alerts
Create a solid portfolio with EVOK
About Evoke Pharma, Inc.
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.42$ per share.
The book value per share is 0.32$
Three months stock forecastAug. 20, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|